(MD) Mednax - Ratings and Ratios

Mednax Inc (NYSE:MD), now operating as Pediatrix Medical Group, Inc., is a leading provider of specialized pediatric and maternal healthcare services in the United States. Founded in 1979 and headquartered in Sunrise, Florida, the company has established itself as a key player in neonatal, maternal-fetal, and pediatric care. With a market capitalization of approximately $1.2 billion, Pediatrix operates in the healthcare services sector, offering a range of medical subspecialties that address critical care needs for infants, children, and expectant mothers.

The companys core services include neonatal care, delivered through a network of neonatal physician subspecialists, nurse practitioners, and other pediatric clinicians. This care is provided in specialized hospital units, focusing on premature and high-risk infants. Pediatrix also offers maternal-fetal care, which includes inpatient and outpatient services for expectant mothers and unborn babies. This is supported by maternal-fetal medicine subspecialists, obstetricians, and a team of nurse practitioners, sonographers, and genetic counselors.

Another key area of expertise is pediatric cardiology. The company provides both inpatient and outpatient care for congenital heart defects and acquired heart disease in infants, children, adolescents, and adults. This service is delivered by pediatric cardiologists, nurse practitioners, echocardiographers, and other diagnostic specialists. Additionally, Pediatrix offers specialized cardiac care for fetal, neonatal, and pediatric patients.

Beyond these specialties, Pediatrix provides a broader range of pediatric subspecialty care, including services from pediatric intensivists, hospitalists, surgeons, ophthalmologists, ear, nose, and throat physicians, and gastroenterologists. The company also operates support services in pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments within hospitals.

From a financial perspective, Pediatrix operates with a price-to-sales ratio of 0.60 and a price-to-book ratio of 1.65, indicating a relatively conservative valuation. The forward P/E ratio of 9.07 suggests expectations for moderate earnings growth. The companys focus on specialized, high-acuity care positions it as a critical provider in the U.S. healthcare system, particularly in regions with limited access to pediatric and maternal-fetal subspecialists.